KR-33493 是一种 FAS 相关因子 1 (FAF1) 抑制剂，可用于帕金森病研究。

KR-33493 is a FAS-associated factor 1 (FAF1) inhibitor and can be used in studies about Parkinson's disease.

Bodyweight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period.

In Sprague-Dawley (SD) rats, KR-33493(500 and 1000 mg/kg; oral) shows no significant changes including Bodyweight changes, hematology, serum biochemistry, and urinalysis. In dogs, red blood cell count value in males is significantly higher at the 1000 mg/kg/day dose with KR-33493 and is recovered after the end of the administration period[1].

1021497-97-1

C20H18BrN3O3S

460.34

KR-33494

DMSO:28 mg/mL (60.8 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years